Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Statins and Diabetes: Despite Potential Link, Doctors Still Agree On Cholesterol-Lowering Effectiveness



The article takes a strong stance on the issue, arguing that even if the unproven link was verified, the benefits of statins in preventing heart attacks and strokes far outweighs the minor risk of developing diabetes.

Share this!

January 19, 2017 | by Sarah Hand, M.Sc.

A commentary published in The American Journal of Medicine, has attempted to address the possible link between statins – a class of cholesterol-lowing drugs – and diabetes. The article takes a strong stance on the issue, arguing that even if the unproven link was verified, the benefits of statins in preventing heart attacks and strokes far outweighs the minor risk of developing diabetes.

“The totality of evidence clearly indicates that the more widespread and appropriate utilization of statins, as adjuncts, not alternatives to therapeutic lifestyle changes, will yield net benefits in the treatment and primary prevention of heart attacks and strokes, including among high, medium and low risk patients unwilling or unable to adopt therapeutic lifestyle changes,” said Dr. Charles H. Hennekens, professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and one of three authors of the article.

In a related editorial, Dr. Joseph S. Alpert, editor-in-chief of the journal, as well as professor of medicine at the University of Arizona School of Medicine, agrees with the main points of the article and further emphasizes the challenges of treating and preventing heart disease. “There is no threshold for low density lipoprotein cholesterol below which there are no net benefits of statins either in the treatment or primary prevention of heart attacks and strokes,” said Alpert.

According to the authors, the possible risk of developing diabetes could prevent doctors from prescribing the drugs to patients who could benefit from treatment. Similarly, patients may refuse or cease treatment with statins if they are not properly informed of the benefits, potentially leading to an increase in preventable deaths due to heart attacks and strokes.

“These public health issues are especially alarming in primary prevention, particularly among women, for whom cardiovascular disease also is the leading cause of death, and for whom there is even more underutilization of statins than for men,” said Hennekens. In 2013, the American Heart Association published new guidelines for the use of statins which included broader use in both prevention and treatment of heart disease. Heart disease is responsible for around 600,000 US deaths per year, according to the Centers for Disease Control and Prevention (CDC).

Keywords: Statins, Diabetes, Cholesterol


Share this with your colleagues!

New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News

Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News

Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


Top 5 Most Impactful Tweets from #AAIC17


Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.